CX546
Encyclopedia
CX-546 is an ampakine
drug developed by Cortex Pharmaceuticals.
It has been proposed as a treatment for schizophrenia
. CX-546 was the second drug of note to come out of the Cortex research program, after CX-516
, but while it was an improvement over its predecessor in some respects, it still has problems with limited oral bioavailability.
However CX-546 still represented a significant advance that led on to the development of newer compounds such as CX-614 and CX-717 with superior properties over the earlier drugs. CX-546 itself has been investigated for other applications, and most notably has been found to show significant efficacy in reversing the respiratory depression produced by sedative drugs such as opioid
s and barbiturates.
No effective respiratory stimulants are currently marketed for this application, with CX-546 being only the third drug discovered (after BIMU-8 and BW373U86
) that effectively relieves the respiratory depression induced by fentanyl without reducing the analgesic effects. CX-546 could be developed for this purpose, although it is more likely Cortex will use newer and more potent analogues such as CX-1739 or CX-1763 which are likely to be more suitable for commercial development.http://www.wallstreet-online.de/community/thread/940011-26.html
Ampakine
Ampakines are a class of compounds known to enhance attention span and alertness, and facilitate learning and memory. The ampakines take their name from the glutamatergic AMPA receptor with which they strongly interact...
drug developed by Cortex Pharmaceuticals.
It has been proposed as a treatment for schizophrenia
Schizophrenia
Schizophrenia is a mental disorder characterized by a disintegration of thought processes and of emotional responsiveness. It most commonly manifests itself as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, and it is accompanied by significant social...
. CX-546 was the second drug of note to come out of the Cortex research program, after CX-516
CX-516
CX-516 is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator and is being developed by a collaboration of Cortex and Shire and Servier...
, but while it was an improvement over its predecessor in some respects, it still has problems with limited oral bioavailability.
However CX-546 still represented a significant advance that led on to the development of newer compounds such as CX-614 and CX-717 with superior properties over the earlier drugs. CX-546 itself has been investigated for other applications, and most notably has been found to show significant efficacy in reversing the respiratory depression produced by sedative drugs such as opioid
Opioid
An opioid is a psychoactive chemical that works by binding to opioid receptors, which are found principally in the central and peripheral nervous system and the gastrointestinal tract...
s and barbiturates.
No effective respiratory stimulants are currently marketed for this application, with CX-546 being only the third drug discovered (after BIMU-8 and BW373U86
BW373U86
BW373U86 is an opioid analgesic drug used in scientific research.BW373U86 is a selective agonist for the δ-opioid receptor, with approximately 15x stronger affinity for the δ-opioid than the μ-opioid receptor...
) that effectively relieves the respiratory depression induced by fentanyl without reducing the analgesic effects. CX-546 could be developed for this purpose, although it is more likely Cortex will use newer and more potent analogues such as CX-1739 or CX-1763 which are likely to be more suitable for commercial development.http://www.wallstreet-online.de/community/thread/940011-26.html